Literature DB >> 16278670

Stabilization of prolactin receptor in breast cancer cells.

Y Li1, C V Clevenger, N Minkovsky, K G S Kumar, P N Raghunath, J E Tomaszewski, V S Spiegelman, S Y Fuchs.   

Abstract

The role of the hormone prolactin (PRL) in the pathogenesis of breast cancer is mediated by its cognate receptor (PRLr). Ubiquitin-dependent degradation of the PRLr that negatively regulates PRL signaling is triggered by PRL-mediated phosphorylation of PRLr on Ser349 followed by the recruitment of the beta-transducin repeats-containing protein (beta-TrCP) ubiquitin-protein isopeptide ligase. We report here for the first time that interaction between PRLr and beta-TrCP is less efficient in human breast cancer cells than in non-tumorigenic human mammary epithelial cells. Furthermore, we demonstrate that both PRLr degradation and PRLr phosphorylation on Ser349 are impaired in breast tumor cells and tissues, an observation that directly correlates with enhanced expression of the PRLr in malignant breast epithelium. These findings represent a novel mechanism through which altered PRLr stability may directly influence the pathogenesis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16278670     DOI: 10.1038/sj.onc.1209214

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  24 in total

1.  Ubiquitination-dependent regulation of signaling receptors in cancer.

Authors:  Wei-Chun Huangfu; Serge Y Fuchs
Journal:  Genes Cancer       Date:  2010-07

Review 2.  Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Authors:  Christopher J Carbone; Serge Y Fuchs
Journal:  J Cell Biochem       Date:  2014-01       Impact factor: 4.429

3.  HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Yi Liu; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2011-08-04

4.  Cyclophilin A Function in Mammary Epithelium Impacts Jak2/Stat5 Signaling, Morphogenesis, Differentiation, and Tumorigenesis in the Mammary Gland.

Authors:  Sonja E Volker; Shannon E Hedrick; Yvonne B Feeney; Charles V Clevenger
Journal:  Cancer Res       Date:  2018-06-29       Impact factor: 12.701

Review 5.  Regulation of prolactin receptor levels and activity in breast cancer.

Authors:  G Swaminathan; B Varghese; S Y Fuchs
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

6.  Prolactin and prolactin receptor expression in cervical intraepithelial neoplasia and cancer.

Authors:  Rafael Ascencio-Cedillo; Edgar Ivan López-Pulido; José Francisco Muñoz-Valle; Nicolás Villegas-Sepúlveda; Susana Del Toro-Arreola; Ciro Estrada-Chávez; Adrian Daneri-Navarro; Ramón Franco-Topete; Delia Pérez-Montiel; Alejandro García-Carrancá; Ana Laura Pereira-Suárez
Journal:  Pathol Oncol Res       Date:  2014-07-03       Impact factor: 3.201

7.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

8.  Impaired turnover of prolactin receptor contributes to transformation of human breast cells.

Authors:  Alexandr Plotnikov; Bentley Varghese; Thai H Tran; Chengbao Liu; Hallgeir Rui; Serge Y Fuchs
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

Review 9.  Modulation of growth hormone receptor abundance and function: roles for the ubiquitin-proteasome system.

Authors:  Stuart J Frank; Serge Y Fuchs
Journal:  Biochim Biophys Acta       Date:  2008-06-09

10.  Increased expression of the prolactin receptor is associated with malignant laryngeal tumors.

Authors:  Luis R González-Lucano; José F Muñoz-Valle; Rafael Ascencio-Cedillo; José A Domínguez-Rosales; Gonzalo López-Rincón; Susana Del Toro-Arreola; Miriam Bueno-Topete; Adrián Daneri-Navarro; Ciro Estrada-Chávez; Ana L Pereira-Suárez
Journal:  Exp Ther Med       Date:  2012-01-30       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.